Top Markets
#1 MowCat MowCat +781.41%
#2 Islamic Coin Islamic Coin +152.09%
#3 龙虾 (Lobster) 龙虾 (Lobster) +85.82%
#4 Akedo Akedo +57.05%
#5 Magma Finance Magma Finance +42.91%
#6 MarsCoin MarsCoin +32.74%
#7 Pons Pons +32.28%
#8 SIXSEVEN SIXSEVEN +30.44%
#9 DeXe DeXe +27.75%
#10 Cortex Cortex +26.60%
Coin of the day
MowCat MowCat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Classement en actions #7949
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Prix de l'action
$3.11
Capitalisation boursière
$1.41B
Changement (1 jour)
-1.97%
Changement (1 an)
-57.22%
Pays
CN
Échange Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Catégorie

Healthcare
Revenus pour Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Staidson (Beijing) BioPharmaceuticals Co., Ltd., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Staidson (Beijing) BioPharmaceuticals Co., Ltd. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH